ClinicalTrials.gg
No longer availableNCT04869501Updated Apr 28, 2023

Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer

An expanded access record providing TJ004309 and Atezolizumab in Cancer, sponsored by I-Mab Biopharma US Limited. No longer available at 3 sites in United States. Per ClinicalTrials.gov, last updated 2023-04-28.

Sponsored by I-Mab Biopharma US Limited · Expanded access

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Intermediate-size population
Sex
All
01

Study summary

This expanded access protocol was designed to provide TJ004309 in combination with atezolizumab to the remaining three patients with advanced or metastatic cancer who plan to continue with treatment.

02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

Browse Neoplasms studies →

Lead sponsor

I-Mab Biopharma US Limited is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participation in the Tracon sponsored 4309ST101 or I-Mab sponsored TJ004309STM103 study and thought to have potential to derive clinical benefit from continued treatment in the opinion of the parent study investigator from dosing of TJ004309 in combination with atezolizumab.
  2. Willing or able to comply with study treatment and standard of care testing and procedures.

Exclusion criteria

Exclusion Criteria:

  1. Any unresolved ongoing toxicity or clinical event that would make continued treatment with TJ004309 inappropriate.
  2. Current treatment in another clinical study or treatment with other standard of care therapy.
  3. Currently pregnant.
  4. Current evidence of any condition (including medical, psychiatric or substance abuse disorder), therapy, or laboratory abnormality that might interfere with the patient's participation or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
05

Access details

Study type
Expanded access
Access type
Intermediate-size population

Available treatment

06

Where to request access

3 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • HonorHealth Research Institute
    Scottsdale, Arizona 85258, United States
  • Arizona Oncology Associates, P.C.
    Tucson, Arizona 85704, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT04869501
Lead sponsor
I-Mab Biopharma US Limited
Responsible party
Sponsor
First posted
May 3, 2021
Last update
Apr 28, 2023
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion